K2 Principal Fund, L.P. I Teos Therapeutics, Inc. Transaction History
K2 Principal Fund, L.P.
- $307 Million
- Q4 2024
A detailed history of K2 Principal Fund, L.P. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 184,500 shares of ITOS stock, worth $1.37 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
184,500
Previous 403,700
54.3%
Holding current value
$1.37 Million
Previous $4.12 Million
65.64%
% of portfolio
0.46%
Previous 1.96%
Shares
3 transactions
Others Institutions Holding ITOS
# of Institutions
150Shares Held
33.4MCall Options Held
454KPut Options Held
2.45M-
Black Rock Inc. New York, NY3.73MShares$27.6 Million0.0% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$20.3 Million16.91% of portfolio
-
Bvf Inc San Francisco, CA2.33MShares$17.2 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.09MShares$15.5 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY2.07MShares$15.3 Million0.0% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $264M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...